ARDELYX INC (ARDX) Fundamental Analysis & Valuation

NASDAQ:ARDX • US0396971071

Current stock price

5.96 USD
+0.41 (+7.39%)
Last:

This ARDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ARDX Profitability Analysis

1.1 Basic Checks

  • In the past year ARDX has reported negative net income.
  • In the past year ARDX has reported a negative cash flow from operations.
  • In the past 5 years ARDX always reported negative net income.
  • In the past 5 years ARDX always reported negative operating cash flow.
ARDX Yearly Net Income VS EBIT VS OCF VS FCFARDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • ARDX has a Return On Assets of -12.28%. This is amongst the best in the industry. ARDX outperforms 81.24% of its industry peers.
  • The Return On Equity of ARDX (-36.90%) is better than 70.60% of its industry peers.
Industry RankSector Rank
ROA -12.28%
ROE -36.9%
ROIC N/A
ROA(3y)-14.49%
ROA(5y)-36.87%
ROE(3y)-33.03%
ROE(5y)-71.79%
ROIC(3y)N/A
ROIC(5y)N/A
ARDX Yearly ROA, ROE, ROICARDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • With an excellent Gross Margin value of 90.29%, ARDX belongs to the best of the industry, outperforming 92.07% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ARDX has declined.
  • The Profit Margin and Operating Margin are not available for ARDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y-1.65%
ARDX Yearly Profit, Operating, Gross MarginsARDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ARDX Health Analysis

2.1 Basic Checks

  • ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ARDX has been increased compared to 1 year ago.
  • ARDX has more shares outstanding than it did 5 years ago.
  • ARDX has a worse debt/assets ratio than last year.
ARDX Yearly Shares OutstandingARDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ARDX Yearly Total Debt VS Total AssetsARDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • ARDX has an Altman-Z score of 1.04. This is a bad value and indicates that ARDX is not financially healthy and even has some risk of bankruptcy.
  • ARDX's Altman-Z score of 1.04 is fine compared to the rest of the industry. ARDX outperforms 62.86% of its industry peers.
  • ARDX has a Debt/Equity ratio of 1.21. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 1.21, ARDX is not doing good in the industry: 76.40% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Altman-Z 1.04
ROIC/WACCN/A
WACC9.55%
ARDX Yearly LT Debt VS Equity VS FCFARDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • ARDX has a Current Ratio of 4.31. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
  • ARDX's Current ratio of 4.31 is in line compared to the rest of the industry. ARDX outperforms 49.90% of its industry peers.
  • A Quick Ratio of 4.11 indicates that ARDX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 4.11, ARDX is in line with its industry, outperforming 50.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.31
Quick Ratio 4.11
ARDX Yearly Current Assets VS Current LiabilitesARDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ARDX Growth Analysis

3.1 Past

  • ARDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.37%.
  • ARDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.09%.
  • ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 121.91% yearly.
EPS 1Y (TTM)-53.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)22.09%
Revenue growth 3Y98.4%
Revenue growth 5Y121.91%
Sales Q2Q%7.82%

3.2 Future

  • The Earnings Per Share is expected to grow by 60.50% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 27.78% on average over the next years. This is a very strong growth
EPS Next Y112.61%
EPS Next 2Y104.16%
EPS Next 3Y90.45%
EPS Next 5Y60.5%
Revenue Next Year37.43%
Revenue Next 2Y35.83%
Revenue Next 3Y34.37%
Revenue Next 5Y27.78%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARDX Yearly Revenue VS EstimatesARDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
ARDX Yearly EPS VS EstimatesARDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

2

4. ARDX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARDX. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 189.10, which means the current valuation is very expensive for ARDX.
  • 88.01% of the companies in the same industry are more expensive than ARDX, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, ARDX is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 189.1
ARDX Price Earnings VS Forward Price EarningsARDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDX Per share dataARDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • ARDX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as ARDX's earnings are expected to grow with 90.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.16%
EPS Next 3Y90.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARDX Dividend Analysis

5.1 Amount

  • No dividends for ARDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARDX Fundamentals: All Metrics, Ratios and Statistics

ARDELYX INC

NASDAQ:ARDX (3/31/2026, 10:47:06 AM)

5.96

+0.41 (+7.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)04-29
Inst Owners69.14%
Inst Owner Change13.57%
Ins Owners2.84%
Ins Owner Change5.48%
Market Cap1.46B
Revenue(TTM)407.32M
Net Income(TTM)-61.60M
Analysts90
Price Target16.2 (171.81%)
Short Float %9.18%
Short Ratio5.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0%
Min EPS beat(2)-100%
Max EPS beat(2)100%
EPS beat(4)2
Avg EPS beat(4)-1.35%
Min EPS beat(4)-100%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)59.25%
EPS beat(12)8
Avg EPS beat(12)48.51%
EPS beat(16)12
Avg EPS beat(16)412.07%
Revenue beat(2)2
Avg Revenue beat(2)5.23%
Min Revenue beat(2)3.91%
Max Revenue beat(2)6.56%
Revenue beat(4)3
Avg Revenue beat(4)5.19%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)18.08%
Revenue beat(8)7
Avg Revenue beat(8)11.24%
Revenue beat(12)10
Avg Revenue beat(12)23.49%
Revenue beat(16)13
Avg Revenue beat(16)23.73%
PT rev (1m)0%
PT rev (3m)35.74%
EPS NQ rev (1m)-13.71%
EPS NQ rev (3m)-310.18%
EPS NY rev (1m)-77.98%
EPS NY rev (3m)-80.62%
Revenue NQ rev (1m)-1.72%
Revenue NQ rev (3m)-10.5%
Revenue NY rev (1m)1.56%
Revenue NY rev (3m)7.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 189.1
P/S 3.59
P/FCF N/A
P/OCF N/A
P/B 8.76
P/tB 8.76
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)0.03
Fwd EY0.53%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS1.66
BVpS0.68
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.28%
ROE -36.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.29%
FCFM N/A
ROA(3y)-14.49%
ROA(5y)-36.87%
ROE(3y)-33.03%
ROE(5y)-71.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y-1.65%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.77%
Cap/Sales 0.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.31
Quick Ratio 4.11
Altman-Z 1.04
F-Score3
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)41.47%
Cap/Depr(5y)51.91%
Cap/Sales(3y)0.32%
Cap/Sales(5y)3.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y112.61%
EPS Next 2Y104.16%
EPS Next 3Y90.45%
EPS Next 5Y60.5%
Revenue 1Y (TTM)22.09%
Revenue growth 3Y98.4%
Revenue growth 5Y121.91%
Sales Q2Q%7.82%
Revenue Next Year37.43%
Revenue Next 2Y35.83%
Revenue Next 3Y34.37%
Revenue Next 5Y27.78%
EBIT growth 1Y-44.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year197.65%
EBIT Next 3Y125.81%
EBIT Next 5Y76.22%
FCF growth 1Y4.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.19%
OCF growth 3YN/A
OCF growth 5YN/A

ARDELYX INC / ARDX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ARDELYX INC (ARDX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ARDX.


Can you provide the valuation status for ARDELYX INC?

ChartMill assigns a valuation rating of 2 / 10 to ARDELYX INC (ARDX). This can be considered as Overvalued.


How profitable is ARDELYX INC (ARDX) stock?

ARDELYX INC (ARDX) has a profitability rating of 2 / 10.


Can you provide the financial health for ARDX stock?

The financial health rating of ARDELYX INC (ARDX) is 3 / 10.